Physician profile
Nolan D Farmer
NPI 1295269934
$1,677.42
in general payments reported to CMS, 2019-2025
21 companies · $310 in 2025
The $310 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.66 · 2020: $29.54 · 2021: $54.47 · 2022: $451 · 2023: $471 · 2024: $350 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,130.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $299.15 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $247.93 | 2020-2024 | Xarelto |
| Astellas Pharma US INC | $235.26 | 2022-2025 | Veozah |
| Pfizer INC. | $179.66 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $166.06 | 2022-2025 | Austedo Xr, Austedo Xr |
| Merck Sharp & Dohme LLC | $107.66 | 2020-2025 | Gardasil 9, Capvaxive, M-M-R II |
| Astrazeneca Pharmaceuticals LP | $103.01 | 2023-2025 | Airsupra, Breztri |
| Lilly USA, LLC | $41.49 | 2024-2025 | Kisunla, Zepbound |
| Biohaven Pharmaceuticals, INC. | $38.45 | 2021 | |
| Dexcom, INC. | $37.60 | 2023-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $27.70 | 2025 | Intellis Adaptivestim |
| Vertex Pharmaceuticals Incorporated | $27.61 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.24 | 2024 | Glassia |
| Sanofi-Aventis U.S. LLC | $24.04 | 2025 | |
| Organon LLC | $23.86 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $19.07 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.35 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.45 | 2022 | |
| Xeris Pharmaceuticals, INC. | $14.39 | 2024 | Keveyis |
| Glaxosmithkline, LLC. | $11.78 | 2022 | |
| Allergan, INC. | $11.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nolan Farmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.